Compare Panacea Biotech with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs SUVEN LIFESCIENCES - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH SUVEN LIFESCIENCES PANACEA BIOTECH/
SUVEN LIFESCIENCES
 
P/E (TTM) x 11.8 19.9 59.4% View Chart
P/BV x 2.8 4.0 70.4% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 PANACEA BIOTECH   SUVEN LIFESCIENCES
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-18
SUVEN LIFESCIENCES
Mar-19
PANACEA BIOTECH/
SUVEN LIFESCIENCES
5-Yr Chart
Click to enlarge
High Rs364338 107.8%   
Low Rs129169 76.2%   
Sales per share (Unadj.) Rs96.852.1 185.7%  
Earnings per share (Unadj.) Rs-12.46.8 -181.7%  
Cash flow per share (Unadj.) Rs-2.98.6 -33.3%  
Dividends per share (Unadj.) Rs01.50 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs50.465.3 77.2%  
Shares outstanding (eoy) m61.25127.28 48.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.54.9 52.4%   
Avg P/E ratio x-19.937.1 -53.5%  
P/CF ratio (eoy) x-86.429.6 -292.2%  
Price / Book Value ratio x4.93.9 126.0%  
Dividend payout %022.0 0.0%   
Avg Mkt Cap Rs m15,10132,272 46.8%   
No. of employees `0002.51.1 228.1%   
Total wages/salary Rs m1,516661 229.3%   
Avg. sales/employee Rs Th2,401.96,132.2 39.2%   
Avg. wages/employee Rs Th614.2611.1 100.5%   
Avg. net profit/employee Rs Th-307.9803.5 -38.3%   
INCOME DATA
Net Sales Rs m5,9286,635 89.3%  
Other income Rs m82242 34.0%   
Total revenues Rs m6,0106,877 87.4%   
Gross profit Rs m8451,604 52.7%  
Depreciation Rs m585221 264.4%   
Interest Rs m1,00638 2,667.9%   
Profit before tax Rs m-6641,587 -41.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m99718 13.7%   
Profit after tax Rs m-760869 -87.4%  
Gross profit margin %14.324.2 59.0%  
Effective tax rate %-14.945.2 -32.9%   
Net profit margin %-12.813.1 -97.8%  
BALANCE SHEET DATA
Current assets Rs m5,6036,232 89.9%   
Current liabilities Rs m6,9101,490 463.7%   
Net working cap to sales %-22.071.5 -30.8%  
Current ratio x0.84.2 19.4%  
Inventory Days Days20686 238.1%  
Debtors Days Days8483 101.4%  
Net fixed assets Rs m9,9414,043 245.9%   
Share capital Rs m61127 48.2%   
"Free" reserves Rs m3,0268,183 37.0%   
Net worth Rs m3,0878,310 37.1%   
Long term debt Rs m5,70718 32,062.4%   
Total assets Rs m16,07610,389 154.7%  
Interest coverage x0.343.1 0.8%   
Debt to equity ratio x1.80 86,311.5%  
Sales to assets ratio x0.40.6 57.7%   
Return on assets %1.58.7 17.5%  
Return on equity %-24.610.5 -235.3%  
Return on capital %3.919.5 20.1%  
Exports to sales %24.00-   
Imports to sales %17.50-   
Exports (fob) Rs m1,424NA-   
Imports (cif) Rs m1,040NA-   
Fx inflow Rs m1,6005,622 28.5%   
Fx outflow Rs m1,1311,799 62.9%   
Net fx Rs m4693,822 12.3%   
CASH FLOW
From Operations Rs m1,180356 332.0%  
From Investments Rs m553-279 -198.5%  
From Financial Activity Rs m-1,644-225 730.1%  
Net Cashflow Rs m90-148 -60.5%  

Share Holding

Indian Promoters % 74.5 63.4 117.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 0.0 -  
FIIs % 1.3 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 36.5 64.7%  
Shareholders   10,259 37,287 27.5%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   STERLING BIOTECH  SANOFI INDIA  ALKEM LABORATORIES  FRESENIUS KABI ONCO.  WOCKHARDT  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 334 Points Lower; IT and Telecom Stocks Witness Huge Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day deep in the red. At the closing bell, the BSE Sensex stood lower by 334 points (down 0.9%).

Related Views on News

SUVEN LIFESCIENCES Surges by 6%; BSE HEALTHCARE Index Up 0.5% (Market Updates)

Oct 22, 2019 | Updated on Oct 22, 2019

SUVEN LIFESCIENCES share price has surged by 6% and its current market price is Rs 284. The BSE HEALTHCARE is up by 0.5%. The top gainers in the BSE HEALTHCARE Index is SUVEN LIFESCIENCES (up 5.7%). The top losers are AJANTA PHARMA and CADILA HEALTHCARE .

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Oct 22, 2019 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - SANOFI INDIA COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS